Core Viewpoint - Xali Gold Corp. has initiated engineering studies to update the Feasibility Study for its Pico Machay Gold Project, originally completed in 2009, with a focus on mineral processing and recovery optimization [1][3]. Engineering and Technical Studies - Adam Johnston, an experienced metallurgist, has been engaged to lead the engineering team for the updated Feasibility Study, focusing on mineral processing and metallurgical testing [1][2]. - The updated study will begin with a new Mineral Resource Estimate, followed by revised capital and operational cost estimates, culminating in a Preliminary Economic Assessment (PEA) [3]. - The company is also conducting additional metallurgical testwork to support the Feasibility Study and refine exploration targets for future drilling [3]. Project Development and Resource Estimation - Phase I of the systematic relogging of historical reverse-circulation drill cuttings has been completed, which will enhance the understanding of mineralization controls and support mine planning [4]. - Pico Machay is located in a historically productive mining district in the Southern Peru Epithermal Gold-Silver Belt, benefiting from existing infrastructure and community support [5]. Resource Potential - The Pico Machay project hosts a Historical Measured and Indicated Resource of 264,600 ounces of gold and an additional Historical Inferred Resource of 446,000 ounces of gold, based on historical drilling data [6]. - Previous engineering studies indicated a low-cost open pit heap-leach operation, with significant upside potential given that earlier studies were based on a long-term gold price of $700 per ounce [7].

Core Insights - Hope Therapeutics, a subsidiary of NRx Pharmaceuticals, has formed a strategic partnership with Emobot Health to implement an AI-driven emotional monitoring platform in its interventional psychiatry clinics, marking a significant advancement in the treatment of Treatment-Resistant Depression (TRD) [1][6]. Company Overview - Hope Therapeutics specializes in treating severe mental health conditions, including suicidal depression, PTSD, and TRD, utilizing neuroplastic therapies such as IV Ketamine and Transcranial Magnetic Stimulation (TMS) [9]. - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system disorders, including suicidal depression and chronic pain [10]. Technology and Innovation - Emobot's "Depression Thermometer" replaces traditional psychometric questionnaires with a passive monitoring application that analyzes facial expressions, vocal tones, and actigraphy to assess depression and potential suicidality [2][6]. - The technology aims to address a critical gap in TRD care, where approximately 50% of patients experience relapse within 6 to 12 months, often going undetected between clinic visits [3][6]. Clinical Validation - Preliminary evidence from three prospective studies indicates strong concordance between Emobot's technology and established clinical scales, with a correlation coefficient of r=0.89 for the MADRS scale and r=0.83 for the PHQ-9 scores, demonstrating high sensitivity to change [4][6]. Patient Empowerment - The Emobot app provides patients with real-time insights into their mood, sleep, and physical activity, allowing them to actively participate in their recovery and understand their emotional triggers [5][7]. - Automatic notifications can be sent to patients if a potential relapse is detected, enabling them to reschedule consultations promptly [7]. Future Outlook - The integration of Emobot's platform is expected to double patient success rates by facilitating timely interventions when early signs of relapse are identified [4][6].

Core Viewpoint - The U.S. Patent and Trademark Office's PTAB upheld 23 claims of Seer's U.S. Patent No. 11,435,360, affirming the validity of the technology behind Seer's Proteograph® Product Suite [1][3]. Patent Details - The '360 Patent encompasses methods for analyzing biological samples using engineered nano- and microparticles, which enhance protein enrichment essential for Seer's Proteograph platform [2]. - Out of 29 claims, 23 remain valid, including 5 challenged claims and 18 unchallenged claims, protecting Seer's nanoparticle protein enrichment technology [3]. Technology and Market Position - The upheld claims focus on detecting proteins across a broad concentration range and particle-related aspects of Seer's technology, facilitating deep proteomic analysis [3]. - Seer's Proteograph Product Suite combines proprietary engineered nanoparticles, automation instrumentation, and analytical software, enabling scalable and unbiased proteomics [4]. - The company holds an extensive intellectual property portfolio with over 240 issued patents and pending applications globally, including 80 issued patents [4]. Company Overview - Seer, Inc. is recognized for setting standards in deep, unbiased proteomics, providing insights with unprecedented scale, speed, precision, and reproducibility [5].

Core Viewpoint - Aquestive Therapeutics has successfully completed a Type A meeting with the FDA regarding the resubmission of its New Drug Application (NDA) for Anaphylm™ (dibutepinephrine) sublingual film, aimed at treating Type 1 allergic reactions, including anaphylaxis [1][2] Group 1: FDA Interaction and Study Design - The Type A meeting confirmed the company's approach on key program elements and received clarifying feedback on pharmacokinetic (PK) and human factors (HF) study designs [2][7] - The FDA provided preliminary comments on the PK study design, focusing on consistency with past studies, and the company plans to address this feedback [2][3] - The FDA recommended changes to user groups in the HF study design, and the company believes there is alignment on key elements following discussions during the meeting [3] Group 2: Product Details and Market Potential - Anaphylm™ is a polymer matrix-based epinephrine prodrug that is designed for easy administration without the need for water or swallowing, making it a unique oral epinephrine rescue medication [5] - The product is expected to be the first and only FDA-approved, non-invasive, orally delivered epinephrine product for severe allergic reactions, which could transform treatment options for patients at risk [4][8] Group 3: Future Plans and Regulatory Submissions - The company reaffirms its guidance to resubmit the Anaphylm NDA in the third quarter of 2026 and is also advancing regulatory submissions in Canada and the European Union [4][7] - The company is preparing for human factors and pharmacokinetic studies to support the planned NDA resubmission [2][4]

Core Viewpoint - Smart Share Global Limited has received an exception from Nasdaq regarding the filing of its Interim Report for the fiscal half-year ended June 30, 2025, allowing the company to regain compliance with Nasdaq's listing requirements [1][2]. Group 1: Nasdaq Compliance - Nasdaq Staff notified the company on January 14, 2026, that it had not complied with the filing requirements as per Listing Rule 5250(c)(1) due to the absence of the Interim Report [2]. - The exception granted by Nasdaq requires the company to file the Interim Report by June 29, 2026, to avoid potential delisting [3]. - If the company fails to meet the terms of the exception, it has the right to appeal to a Hearings Panel regarding the potential delisting of its securities [3]. Group 2: Company Overview - Smart Share Global Limited, also known as Energy Monster, is a leading consumer tech company in China that provides mobile device charging services through shared power banks [5]. - As of December 31, 2024, the company operated 9.6 million power banks located in 1,279,900 points of interest (POIs) across over 2,200 counties and county-level districts in China [5]. - The company's service allows users to access power banks by scanning QR codes on its cabinets, which are placed in various public venues such as entertainment spots, restaurants, and transportation hubs [5].

Core Insights - USA Rare Earth, Inc. is establishing itself as a global leader in the rare earth industry by executing an integrated growth strategy that includes mining, processing, metal-making, and magnet manufacturing [2][22] - The company has secured significant funding, including a proposed $1.6 billion from the U.S. Department of Commerce, to accelerate its business plan and enhance its capabilities in the rare earth supply chain [2][7] - The acquisition of Less Common Metals Ltd. has strengthened the company's position by adding internal metal-making capabilities and enhancing revenue through product sales [5][22] Financial Highlights - As of December 31, 2025, the company reported cash and cash equivalents of $359.9 million and no significant debt [5] - The operating loss for FY 2025 was $59.5 million, with operating expenses totaling $59.7 million [5][11] - The net loss attributable to USA Rare Earth for the year was $297.6 million, translating to a net loss per share of $3.31 [11][27] Business Highlights - The company completed the acquisition of Less Common Metals in November 2025, which is expected to enhance its revenue and support magnet manufacturing [5][22] - A hydrometallurgical demonstration facility in Colorado is set to begin operations in 2026, supporting the Round Top project and commercial plant design [5][8] - The company has established strategic partnerships, including an agreement with Solvay SA to supply rare earth metals for advanced magnet production [5][8] Recent Developments - In January 2026, the company proposed a collaboration with the U.S. Government to enhance domestic rare earth capabilities, aiming to create the largest domestic platform for heavy rare earths by 2030 [7][8] - A $1.5 billion capital raise through a common stock PIPE was completed in January 2026, which will support the company's growth objectives [7][8] - The company has initiated the expansion of its magnet manufacturing capacity, targeting a run rate of 600 metric tons per year by the end of Q4 2026 [6][8] 2026 Outlook - The company plans to acquire Texas Mineral Resources Corporation, which will streamline operations and enhance the Round Top project [8] - The commissioning of the hydrometallurgical demonstration facility is expected in Q2 2026, with multiple demonstrations planned to validate processes [8] - The company aims to reach 3,000 metric tons per year of metal-making and alloy capacity at Less Common Metals by the end of 2026 to meet growing demand [9]

VANCOUVER, Canada, March 30, 2026 (GLOBE NEWSWIRE) -- Oroco Resource Corp. (TSX-V: OCO, OTC: ORRCF) (“Oroco” or the “Company”) announces the resignation of Richard Lock as Chief Executive Officer and a director of the Company for personal reasons, effective April 30, 2026. Mr. Lock commented: “I am grateful for the opportunity to have led Oroco since April 2022 and for the dedication of the team in advancing the Santo Tomás Project and the Company's objectives. It has been a privilege to contribute during t ...

Core Viewpoint - PDS Biotechnology Corporation is making significant progress in its clinical programs and financial management, with a focus on accelerating the approval process for its lead immunotherapy product, PDS0101, targeting HPV16-positive head and neck cancer [2][3]. Clinical and Corporate Update - The company amended the VERSATILE-003 Phase 3 clinical trial protocol to include progression-free survival (PFS) as an interim primary endpoint, which is expected to shorten trial duration and reduce costs while maintaining median overall survival as the primary endpoint for full FDA approval [9]. - PDS0101 is positioned as a promising treatment option for patients with HPV16-positive head and neck cancer, addressing a significant unmet medical need [3]. - Early results from the NCI-led trial of PDS01ADC showed a median PFS of 9.6 months and a median PSA decline of 40% in patients with metastatic castration-resistant prostate cancer [9]. Financial Results - For the year ended December 31, 2025, the net loss was approximately $34.5 million, or $0.74 per share, a decrease from a net loss of $37.6 million, or $1.03 per share in 2024 [6][20]. - Research and development expenses decreased to $19.0 million from $22.6 million in 2024, primarily due to reduced manufacturing and personnel costs [7]. - General and administrative expenses also decreased to $12.5 million from $13.8 million in 2024, mainly due to lower personnel costs [8]. - Total operating expenses for 2025 were $31.5 million, down from $36.3 million in 2024 [10][20]. - The company's cash balance as of December 31, 2025, was $26.7 million, down from $41.7 million in 2024 [19].

Core Viewpoint - Vireo Growth Inc. is moving forward with the acquisition of The Hawthorne Gardening Company from ScottsMiracle-Gro, which is expected to enhance Vireo's position in the indoor and hydroponic gardening market in North America [1][2]. Transaction Details - The Hawthorne Transaction involves Vireo acquiring Hawthorne for at least US$35 million in cash, approximately US$50 million in net working capital, and around US$20 million in inventory, primarily soil, to be supplied over two years [2]. - In exchange, Vireo will issue 206 million subordinate voting shares and warrants to purchase an additional 80 million shares at an exercise price of US$0.85 per share, exercisable for five years [2]. Board Appointment - Following the completion of the transaction and shareholder approval, Chris Hagedorn, Executive Vice President of ScottsMiracle-Gro, will be appointed to Vireo's Board of Directors [2]. Conditions for Completion - The completion of the Hawthorne Transaction is subject to the negotiation and execution of definitive agreements and obtaining all necessary regulatory approvals, including those from the Canadian Securities Exchange [3].

Core Viewpoint - Apollo Silver Corp. successfully held its Annual General Meeting (AGM) on March 27, 2026, where all proposed matters were approved by shareholders, including the election of directors and the re-appointment of auditors [1][3]. Group 1: Voting Results - The number of directors was set at seven, and all seven nominees were elected with significant support, including Andrew Bowering receiving 98.79% of votes for his position [2]. - The appointment of Davidson and Company LLP as auditors was approved with 99.93% of votes in favor [3]. - The Company's Omnibus Incentive Plan was re-approved with 99.79% of votes for [3]. Group 2: Leadership Changes - Mr. Thomas was appointed as Lead Independent Director, and Mr. Peregoodoff was appointed as Executive Chair of the Board, effective immediately [3][4]. - Mr. Peregoodoff has extensive experience in senior leadership roles and has previously worked with the President and CEO, Ross McElroy, at BHP, which is expected to strengthen the Company's leadership [4][5]. Group 3: Company Commitment - Andrew Bowering will continue to serve as a Director, key advisor, and spokesperson, emphasizing his commitment to the Company's strategy and long-term value creation [6][7]. - The management team is focused on advancing projects and delivering value to shareholders, with strong operational leadership in place [6]. Group 4: Company Overview - Apollo Silver Corp. is advancing the second largest undeveloped primary silver project in the U.S., the Calico Project, which also includes significant barite and zinc credits [8]. - The Company holds an option on the Cinco de Mayo Project in Mexico, which features a high-grade carbonate replacement deposit [8].